Cancer Advisor

Cancer Academy · Disease Hub · V1.5 Lung Cancer & NSCLC A patient-first guide to understanding lung cancer, NSCLC, biomarkers, treatment options, treatment resistance and the evidence behind them. Lung cancer is not one disease. Modern care increasingly depends on the combination of histology, stage, molecular findings, immune biomarkers, previous treatment and the way the cancer responds over time. This Cancer Academy hub organizes those relationships into one navigable knowledge system. Start with the Basics Explore Biomarkers Understand Resistance Educational resource, not medical advice. The information here is intended to help patients and families understand terminology and discuss questions with their healthcare team. It does not diagnose cancer or determine an individual's treatment. 1. Start ...

Flipping the script in unresectable stage III non-small cell lung cancer (NSCLC) by giving neoadjuvant chemoimmunotherapy followed by chemoradiation has the potential to improve outcomes for patients with this difficult-to-treat disease, a team of investigators asserts. The current standard of care for stage III unresectable  NSCLC  is chemoradiation followed by consolidation with the immune checkpoint inhibitor (ICI)  durvalumab  (Imfinzi), based on  results of the phase 3 PACIFIC trial . However, Rajat Thawani, MD, and colleagues from the University of Chicago argue that upfront platinum-based  chemotherapy  with an ICI may help preserve the immune function of tumor-draining lymphatics. In contrast,  immunotherapy  administered concurrently with chemoradiation attenuates systemic immunity responses to checkpoint blockade, they say. “Tumor-draining lymph nodes serve as the site for T-cell activation in mounting an antitumor immune response ...